CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that the Shenyang Research Institute of Chemical Industry (SYRICI) has purchased the Provantis® preclinical software solution suite to manage preclinical processes at its National Center for New Drug Safety Evaluation, Shenyang, China (SYRICI CEC).
Established in 1949, SYRICI CEC, now part of the Sinochem Group, was the first national, comprehensive chemical research institute in China, and the first Chinese safety evaluation institution to achieve OECD GLP (Good Laboratory Practice) certification. SYRICI CEC focuses on the safety assessment of pesticides, medicines, dyestuffs and chemical industrial products, as well as providing a preclinical evaluation service for new drugs and the registration of pesticide and chemical risk assessment.
Provantis will replace SYRICI’s existing in-house developed software solution, delivering increased efficiencies in the collection, storage and reporting of preclinical data. In addition, by harnessing Instem’s SaaS deployment model, SYRICI will benefit from lower infrastructure and support costs, together with the flexibility and scalability to meet changing business demands.
- SYRICI to deploy an extensive suite of modules including General Toxicology, Reproductive Toxicology, Pathology, Protocol Report & Assembly and Data Import
- Contract awarded following a detailed competitive evaluation; Provantis recognized as the global market leader and the overwhelming standard within China, with multiple, proven, successful implementations across the region
- SYRICI to deploy the SaaS delivery model from Instem’s state-of-the-art Shanghai-based data center
- A range of professional services purchased to facilitate quick implementation and a rapid return on investment
Director Hang Su, Assessment Center Integrated Management Department, SYRICI, said, “As we sought to replace our existing system, it was important to choose not only a world-leading product, but also a data management vendor with the knowledge, experience and capabilities to support our continued growth. We believe that Instem and Provantis can meet our aim and we look forward to a successful partnership.”
Neil Donaldson, VP Europe & Asia, Instem, commented, “We are proud to welcome SYRICI as our latest client in China and look forward to forging a long and successful relationship with them. It is particularly pleasing to add SYRICI to our established and rapidly growing SaaS client roster; a trend that we are increasingly seeing across the region as more and more Chinese R&D organizations are recognizing the proven value of Instem’s SaaS and Hosted services.”
Instem’s Provantis solution was the first western toxicology/pathology software to enter into the Chinese market, deploying its initial system in one of the largest and most advanced vivariums during 2006. As the Chinese preclinical market continues to grow, Instem is leading the market, with its Provantis solution deployed at more sites within the region than any competing product.
Instem has an established full-service office in Shanghai and supports organizations through traditional on-site systems, as well as through its SaaS delivery model from a secure, professionally managed data center based in Shanghai.
About Shenyang Research Institute of Chemical Industry (SYRICI)
Shenyang Research Institute of Chemical Industry (SYRICI), established on January 8, 1949, is the first national comprehensive chemical research institute. In May 1999, through the approval of Ministries and Commissions directly under the State Council, SYRICI became a large-scale scientific and technological enterprise unit directly under the central government. In April 2007, under the approval of the State Council, SYRICI was reorganized with a Fortune 500 company China "Sinochem Group" to be a wholly-owned subsidiary.
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit www.instem.com